CoChat

Hepatocellular Carcinoma

Villanueva, Augusto · 2019 · New England Journal of Medicine

The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.

Abstract

Presenting the most up-to-date knowledge of hepatocellular carcinoma, it covers all topics — including those more controversial ones — in this rapidly advancing field, from epidemiology to prevention, from molecular biology to gross pathology, from screening to atypical presentation, from diagnosis to treatment, and from assessment to choice of appropriate treatment. This volume is therefore an important contribution to the field of hepatocellular carcinoma.

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmra1713263

Cites

90 of 90 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 90 references

Research works printed but not linked: 2

  1. Onxeo announces top-line results from ReLive phase III study of Livatag® in advanced hepatocellular carcinoma. Paris: Onxeo September 11 2017 (press release) (https://www.onxeo.com/onxeo-announces-top-line-results-relive-phase-iii-study-livatag-advanced-hepatocellular-carcinoma/).
  2. Merck provides update on KEYNOTE-240 a phase 3 study of KEYTRUDA® (pembrolizumab) in previously treated patients with advanced hepatocellular carcinoma. Kenilworth NJ: Merck February 19 2019 (press release) (https://investors.merck.com/news/press-release-details/2019/Merck-Provides-Update-on-KEYNOTE-240-a-Phase-3-Study-of-KEYTRUDA-pembrolizumab-in-Previously-Treated-Patients-with-Advanced-Hepatocellular-Carcinoma/default.aspx).

Cited by

See all 4,508

Metadata

Authors
Villanueva, A.
Affiliations
Tisch Cancer Institute (US)
Corresponding author
Villanueva, Augusto
Venue
New England Journal of Medicine
Published
2019-04-11
Volume
380
Issue
15
Pages
1450-1462
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4232620598
Cited by
4,508
References
90
Citations by year
2026: 310 · 2025: 455 · 2024: 676 · 2023: 787 · 2022: 918 · 2021: 802 · 2020: 484 · 2019: 74
FWCI
75.28
Type
journal article
Language
en
Open access
closed
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords
hepatocellular carcinoma, primary liver cancer, liver cirrhosis, hepatitis B virus, hepatitis C virus, nonalcoholic steatohepatitis, underlying liver disease, treatment efficacy
MeSH terms
Algorithms, Antineoplastic Agents, Combined Modality Therapy, Carcinoma, Hepatocellular, Humans, Liver, Liver Neoplasms, Magnetic Resonance Imaging, Neoplasm Staging, Risk Factors, Tomography, X-Ray Computed, Ablation Techniques, Early Detection of Cancer

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hepatocellular Carcinoma. https://app.cochat.ai/papers/10.1056/nejmra1713263
The paper
Villanueva, A. (2019). Hepatocellular Carcinoma. New England Journal of Medicine. https://doi.org/10.1056/nejmra1713263

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.